270 related articles for article (PubMed ID: 32546788)
1. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis.
Jain N; Kalam H; Singh L; Sharma V; Kedia S; Das P; Ahuja V; Kumar D
Nat Commun; 2020 Jun; 11(1):3062. PubMed ID: 32546788
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ABCG2 efflux pumps renders the Mycobacterium tuberculosis hiding in mesenchymal stem cells responsive to antibiotic treatment.
Kaur S; Angrish N; Gupta K; Tyagi AK; Khare G
Infect Genet Evol; 2021 Jan; 87():104662. PubMed ID: 33278633
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and Clinical Evidence of Mycobacterium tuberculosis Persistence in the Hypoxic Niche of Bone Marrow Mesenchymal Stem Cells after Therapy.
Garhyan J; Bhuyan S; Pulu I; Kalita D; Das B; Bhatnagar R
Am J Pathol; 2015 Jul; 185(7):1924-34. PubMed ID: 26066709
[TBL] [Abstract][Full Text] [Related]
4. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
Genestet C; Bernard-Barret F; Hodille E; Ginevra C; Ader F; Goutelle S; Lina G; Dumitrescu O;
Tuberculosis (Edinb); 2018 Jul; 111():67-70. PubMed ID: 30029917
[TBL] [Abstract][Full Text] [Related]
5. Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis.
Singh VK; Mishra A; Bark S; Mani A; Subbian S; Hunter RL; Jagannath C; Khan A
Microbes Infect; 2020 Oct; 22(9):423-431. PubMed ID: 32562667
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
7. The SecA2 pathway of Mycobacterium tuberculosis exports effectors that work in concert to arrest phagosome and autophagosome maturation.
Zulauf KE; Sullivan JT; Braunstein M
PLoS Pathog; 2018 Apr; 14(4):e1007011. PubMed ID: 29709019
[TBL] [Abstract][Full Text] [Related]
8. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis.
Das B; Kashino SS; Pulu I; Kalita D; Swami V; Yeger H; Felsher DW; Campos-Neto A
Sci Transl Med; 2013 Jan; 5(170):170ra13. PubMed ID: 23363977
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.
Zhang X; Xie Q; Ye Z; Li Y; Che Z; Huang M; Zeng J
Front Immunol; 2021; 12():695278. PubMed ID: 34367155
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium tuberculosis with different virulence reside within intact phagosomes and inhibit phagolysosomal biogenesis in alveolar macrophages of patients with pulmonary tuberculosis.
Ufimtseva E; Eremeeva N; Bayborodin S; Umpeleva T; Vakhrusheva D; Skornyakov S
Tuberculosis (Edinb); 2019 Jan; 114():77-90. PubMed ID: 30711161
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid-induced control of Mycobacterium tuberculosis by primary human cells requires interleukin-1 receptor and tumor necrosis factor.
Yamashiro LH; Eto C; Soncini M; Horewicz V; Garcia M; Schlindwein AD; Grisard EC; Rovaris DB; Báfica A
Eur J Immunol; 2016 Aug; 46(8):1936-47. PubMed ID: 27230303
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Integrating Multifaceted Information to Predict Mycobacterium tuberculosis-Human Protein-Protein Interactions.
Sun J; Yang LL; Chen X; Kong DX; Liu R
J Proteome Res; 2018 Nov; 17(11):3810-3823. PubMed ID: 30269499
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy.
Khan A; Mann L; Papanna R; Lyu MA; Singh CR; Olson S; Eissa NT; Cirillo J; Das G; Hunter RL; Jagannath C
Sci Rep; 2017 Nov; 7(1):15010. PubMed ID: 29118429
[TBL] [Abstract][Full Text] [Related]
15. IL-10 blocks phagosome maturation in mycobacterium tuberculosis-infected human macrophages.
O'Leary S; O'Sullivan MP; Keane J
Am J Respir Cell Mol Biol; 2011 Jul; 45(1):172-80. PubMed ID: 20889800
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of Mycobacterium tuberculosis-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis.
Mzinza DT; Sloan DJ; Jambo KC; Shani D; Kamdolozi M; Wilkinson KA; Wilkinson RJ; Davies GR; Heyderman RS; Mwandumba HC
Tuberculosis (Edinb); 2015 Jul; 95(4):463-9. PubMed ID: 26051653
[TBL] [Abstract][Full Text] [Related]
17. HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection.
Campo M; Heater S; Peterson GJ; Simmons JD; Skerrett SJ; Mayanja-Kizza H; Stein CM; Boom WH; Hawn TR
Tuberculosis (Edinb); 2021 Mar; 127():102062. PubMed ID: 33639591
[TBL] [Abstract][Full Text] [Related]
18. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA
mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Subbian S; Tsenova L; O'Brien P; Yang G; Koo MS; Peixoto B; Fallows D; Dartois V; Muller G; Kaplan G
PLoS Pathog; 2011 Sep; 7(9):e1002262. PubMed ID: 21949656
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium tuberculosis nucleoside diphosphate kinase inactivates small GTPases leading to evasion of innate immunity.
Sun J; Singh V; Lau A; Stokes RW; Obregón-Henao A; Orme IM; Wong D; Av-Gay Y; Hmama Z
PLoS Pathog; 2013; 9(7):e1003499. PubMed ID: 23874203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
